Torrent Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Torrent Pharmaceuticals is navigating a transformative phase following its acquisition of JB Chemicals, which is yielding significant cost synergies and enhancing its competitive position in the Indian pharmaceutical market. Management's optimistic outlook is supported by robust domestic growth, particularly in chronic therapies, and a successful entry into the semaglutide market. However, the company faces near-term challenges, including supply chain disruptions and margin pressures due to integration costs. Vista's financial outlook reflects an expectation of accelerating revenue growth, although margins may remain under pressure. The premium valuation suggests that the market is pricing in these growth prospects, with a target price indicating modest upside. Over the next 12-24 months, Torrent's strategic focus on high-margin products and operational efficiencies will be critical in mitigating risks associated with integration and regulatory challenges. The overall sentiment remains cautiously optimistic, bolstered by favorable currency movements and a strong product pipeline, despite potential headwinds from pricing pressures and execution risks during the integration phase
Why We Like This Stock
- Successful integration of JB Chemicals is expected to yield significant cost synergies and enhance market positioning
- Strong domestic growth in chronic therapies and a robust pipeline, including semaglutide, supports revenue acceleration
- Management's focus on operational efficiencies and high-margin products positions the company favorably for long-term growth
Things To Watch Out For
- Short-term supply chain disruptions and integration-related costs are pressuring margins
- Potential price erosion in the US generic market and regulatory challenges could impact profitability
- Execution risks during the integration phase may hinder the realization of projected synergies
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 10,728 | 11,516 | 13,980 | 17,630 | 21,773 |
| Profit Before Tax (Cr.) | 2,246 | 2,679 | 2,961 | 2,489 | 3,884 |
| PBT Margin | 20.9% | 23.3% | 2118.0% | 14.1% | 17.8% |
| Net Profit (Cr.) | 1,815 | 2,058 | 2,091 | 1,746 | 2,725 |
| Earnings Per Share | 53.6 | 60.8 | 61.8 | 51.6 | 80.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BPWealth | ▲ Buy | nan | 25-May-2026 |
| Elara Capital | ► Accumulate | 4,351 | 23-Apr-2026 |
| HDFC Securities | ► Add | 5,270 | 30-Jul-2026 |
| HSBC | ▲ Buy | 5,375 | 31-Jul-2026 |
| ICICI Securities | ► Hold | 4,925 | 31-Jul-2026 |
| Jeffries | ▲ Buy | 5,350 | 25-May-2026 |
| Macguire | ▲ Outperform | 5,000 | 31-Jul-2026 |
| Morgan Stanley | ▲ Overweight | 5,623 | 31-Jul-2026 |
| Motilal Oswal | ► Neutral | 4,730 | 31-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 5,500 | 31-Jul-2026 |
Company Overview
Show Company Profile
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.